Free tool
FAERS Monitor: Horizant
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022399 or its brand name (Horizant, Gabapentin Enacarbil). Reports on generic versions are filed under their own applications.
Reports
2,844
Serious
1,590
56% of reports
Hospitalization
394
Death reported
700
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- toxicity to various agents594
- completed suicide277
- drug ineffective217
- off label use187
- drug abuse138
- dizziness126
- somnolence125
- nausea122
- insomnia116
- cardio-respiratory arrest110
- headache110
- fatigue99
- feeling abnormal95
- pain89
- dyspnoea88
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 32 |
| 2012 | 104 |
| 2013 | 59 |
| 2014 | 35 |
| 2015 | 92 |
| 2016 | 206 |
| 2017 | 340 |
| 2018 | 352 |
| 2019 | 442 |
| 2020 | 308 |
| 2021 | 212 |
| 2022 | 293 |
| 2023 | 119 |
| 2024 | 89 |
| 2025 | 100 |
| 2026 | 61 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,315 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxicity to various agentsSignal | 594 | 26.1 | 24.3 | 14,401 |
| completed suicideSignal | 277 | 24.7 | 22.0 | 6,269 |
| cardio-respiratory arrestSignal | 110 | 19.5 | 16.2 | 1,911 |
| drug abuseSignal | 138 | 12.3 | 10.4 | 1,422 |
| somnolenceSignal | 125 | 4.6 | 3.9 | 351 |
| insomniaSignal | 116 | 3.2 | 2.7 | 178 |
| feeling abnormalSignal | 95 | 2.9 | 2.4 | 120 |
| dizziness | 126 | 1.9 | 1.6 | 51 |
| off label use | 187 | 1.6 | 1.4 | 41 |
| headache | 110 | 1.3 | 1.1 | 7 |
| drug ineffective | 217 | 1.2 | 1.1 | 9 |
| dyspnoea | 88 | 1.1 | 0.9 | 2 |
| nausea | 122 | 1.1 | 1.0 | 2 |
| pain | 89 | 1.1 | 0.9 | 0 |
| fatigue | 99 | 0.9 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.